A collaboration over four gene therapy programmes substantially beefs up Neurocrine’s pipeline, while Voyager Therapeutics gets a much-needed infusion of credibility.
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.
Companies that want to play in rare diseases need to shop for gene therapies, but price tags are looking rich.
Axovant transforms itself into a new gene therapy company with an old Oxford Biomedica product.
Takeda's appetite for risk in early stage neuroscience could make it one to watch.